Haleon plc announced the launch of its new Parodontax Gum Strengthen & Protect Toothpaste and Mouthwash on March 12, 2026. The daily oral‑care line incorporates hyaluronic acid, a moisturizing and anti‑inflammatory ingredient that is designed to strengthen the gum seal and provide long‑term protection for users.
The launch comes on the heels of Haleon’s full‑year 2025 earnings, which showed a slight decline in revenue but an increase in profitability. Management highlighted that 60% of the business gained or maintained market share, yet organic revenue growth of 3% fell short of medium‑term expectations due to a weak cold‑and‑flu season and low consumer confidence in North America. The company also reported strong gross‑margin improvement and double‑digit organic profit growth, coupled with robust cash generation. “Our brands again proved their resilience, and we continued to outperform the market, with 60% of the business gaining or maintaining share this year. Organic revenue growth of 3% was below our medium‑term expectations, primarily reflecting a weak cold & flu season and low consumer confidence in North America. We delivered strong gross margin improvement and double‑digit organic profit growth, combined with strong cash generation.”
The daily gum‑care segment is expanding, driven by growing consumer awareness of the link between oral and overall health. While specific market‑size figures are not disclosed, the broader oral‑care market remains substantial, with toothpaste dominating sales. Haleon’s new line is positioned to capture a share of this growth by offering a product that blends a proven gum‑expert brand with a novel ingredient.
Parodontax has long been recognized as a “gum expert” brand, and the addition of hyaluronic acid differentiates the new line from competitors that rely on traditional fluoride or antibacterial agents. By targeting consumers who prioritize preventative health, Haleon aims to strengthen its foothold in the daily gum‑care niche and drive category growth.
The launch aligns with Haleon’s broader strategy to invest in oral‑health innovation, including manufacturing facilities in China and a Global Oral Health Innovation Centre. By expanding its product portfolio with a hyaluronic‑acid‑infused offering, Haleon seeks to reinforce its market leadership and create new revenue opportunities within the growing oral‑health segment.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.